Anti-IL-6R (Tocilizumab biosimilar)
Product | Unit size | Cat. code | Docs. | Qty. | Price | |
---|---|---|---|---|---|---|
Anti-hIL6R-To-hIgG1 Human IL-6R (Tocilizumab) antibody - Human IgG1 |
Show product |
100 µg 1 mg (10 x 100 µg) |
hil6rto-mab1
|
|
Human IgG1 monoclonal antibody (mAb) against human IL-6R
Tocilizumab blocks IL-6R signaling
InvivoGen provides Anti-hIL-6R-hIgG1, the biosimilar of the clinical antibody tocilizumab.
It features:
- the variable region of tocilizumab targeting the human interleukin 6 receptor (IL-6R)
- the IgG1 constant region of tocilizumab mediating high effector functions
InvivoGen's Anti-hIL6R-hIgG1 was generated by recombinant DNA technology, produced in Chinese hamster ovary (CHO) cells, and purified by affinity chromatography. Each lot is functionally tested by flow cytometry and cellular assays (see figures).
Key features of the Anti-hIL6R-hIgG1
- Clinically-relevant variable region targeting human IL-6R (Tocilizumab)
- Human IgG1 constant region for high effector functions
- Inhibition of IL-6-dependent signaling has been validated in HEK-Blue™ IL-6 cellular assays
-
The absence of bacterial contamination has been confirmed
IL-6R background
Tocilizumab (TCZ) is a recombinant, humanized monoclonal antibody (mAb) directed against both soluble and membrane-bound human IL-6R. TCZ exhibits anti-inflammatory activity by inhibiting the binding of the pro-inflammatory cytokine, IL-6 to its receptor [1]. IL-6 exerts its biological effects through IL-6R, and the transmembrane protein gp130. Despite only a few cells expressing IL-6R on their surface, many cells respond to IL-6 due to the existence of soluble IL-6R [2]. TCZ can block both modes of signaling [1]. TCZ has been approved for the treatment of inflammatory diseases and conditions such as rheumatoid arthritis (RA) and cytokine release syndrome (CRS), a side effect of CAR-T therapy. Furthermore, it is under investigation for the treatment of the late-stage hyperinflammation observed in severe COVID‑19 patients [3].
COVID-19 related research
Severe COVID-19 patients have been shown to exhibit high levels of pro-inflammatory cytokines, such as IL-6, which can ultimately initiate life-threatening hyper-inflammation and a “cytokine storm” in the lungs and other organs. Tocilizumab is being explored as a potential therapeutic in the treatment of these patients.
References:
1. Sheppard, M. et al. 2017. Tocilizumab (Actemra). Hum Vaccin Immunother 13, 1972- 1988.
2. Rose-John, S. 2012. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8, 1237-1247.
3. Zhang, S. et al. 2020. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. Clin Drug Investig.
Specifications
Specificity: Human Interleukin-6 receptor (hIL-6R)
Clonality: Monoclonal antibodies
Clone: Tocilizumab (Anti-hIL-6R-hIgG1, kappa)
Control: Human IgG1
Source: CHO cells
Formulation: 0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents.
Tested application: Functional assay
Purification: Purified by affinity chromatography with protein G
Quality control:
- The complete sequence of each antibody construct has been verified.
- Each antibody lot has been functionally validated using HEK-Blue™ IL-6 cellular assays
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cellular assays.
Contents
Anti-hIL6R-To-hIgG1 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:
- hil6rto-mab1: 100 µg
- hil6rto-mab1-1: 10 x 100 µg (1 mg)
The product is shipped at room temperature.
Upon receipt, store at -20°C.
Tags: buy Tocilizumab (anti-IL-6R) | Tocilizumab (anti-IL-6R) supplier | purchase Tocilizumab (anti-IL-6R) | Tocilizumab (anti-IL-6R) cost | Tocilizumab (anti-IL-6R) manufacturer | order Tocilizumab (anti-IL-6R) | Tocilizumab (anti-IL-6R) distributor
Back to the top